Imugene Limited (ASX: IMU), a clinical-stage immune-oncology company, has obtained Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to commence a Phase 1 clinical study for their oncolytic virotherapy candidate, onCARlytics (on-CAR-19, CF33-CD19, HOV4). This milestone allows Imugene to initiate patient recruitment and dosing in a ground-breaking Phase 1 clinical trial called OASIS.
The study aims to evaluate the safety and tolerability of onCARlytics administered intravenously or intratumorally in combination with Blinatumomab in adults with advanced or metastatic solid tumors. By combining Imugene's CF33-CD19 oncolytic virus with Blinatumomab, onCARlytics shows potential in targeting and eliminating solid tumors that were previously untreatable with CD19-targeting biological drugs. Imugene's CEO, Leslie Chong, expressed the significance of this FDA clearance, highlighting the advancements in treating solid tumor cancers and the dedication of Imugene and City of Hopes research and development teams.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
